BioNTech (NASDAQ:BNTX) Stock Price Up 4.4% – Should You Buy?

Shares of BioNTech SE (NASDAQ:BNTX) rose 4.4% during trading on Friday . The company traded as high as $125.40 and last traded at $124.08. Approximately 419,270 shares changed hands during trading, a decline of 48% from the average daily volume of 809,889 shares. The stock had previously closed at $118.84.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Berenberg Bank initiated coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. HSBC boosted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Finally, TD Cowen decreased their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Trading Up 2.4 %

The stock has a market capitalization of $29.18 billion, a price-to-earnings ratio of -57.96 and a beta of 0.22. The company’s 50 day moving average is $113.91 and its 200 day moving average is $99.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the company posted $0.73 EPS. The business’s revenue was up 38.9% on a year-over-year basis. On average, research analysts forecast that BioNTech SE will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Vestcor Inc bought a new stake in shares of BioNTech in the 3rd quarter worth about $784,000. Y Intercept Hong Kong Ltd bought a new stake in BioNTech during the 3rd quarter worth about $718,000. XTX Topco Ltd bought a new stake in BioNTech during the 3rd quarter worth about $459,000. State Street Corp boosted its stake in shares of BioNTech by 2.0% in the 3rd quarter. State Street Corp now owns 155,867 shares of the company’s stock valued at $18,512,000 after purchasing an additional 3,014 shares during the last quarter. Finally, Redmile Group LLC bought a new position in shares of BioNTech in the 3rd quarter valued at about $18,345,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.